Spartalizumab
Jump to navigation
Jump to search
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized |
Target | PD-1 (CD279) |
Clinical data | |
Other names | PDR001 |
ATC code |
|
Identifiers | |
CAS Number | |
UNII | |
KEGG |
Spartalizumab (INN;[1] development code PDR001) is a monoclonal antibody and checkpoint inhibitor that is being investigated for melanoma.
This drug is being developed by Novartis. As of 2018[update], spartalizumab is undergoing Phase III trials.[2]
References
- ^ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117" (PDF). WHO Drug Information. 31 (2).
- ^ Kaplon H, Muralidharan M, Schneider Z, Reichert JM (2020). "Antibodies to watch in 2020". mAbs. 12 (1): 1703531. doi:10.1080/19420862.2019.1703531. PMC 6973335. PMID 31847708.
Categories:
- Articles with short description
- Short description matches Wikidata
- Drugs not assigned an ATC code
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a monoclonal antibody
- Articles containing potentially dated statements from 2018
- All articles containing potentially dated statements
- Monoclonal antibodies
- All stub articles
- Monoclonal antibody stubs